Skip to main content

Hemab Therapeutics Holdings, Inc.

corporate_fare Company Profile

Hemab Therapeutics Holdings, Inc.

COAG·NASDAQ·Life Sciences·CIK 0002114044

Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology company focused on developing new treatments for blood coagulation disorders. The company aims to improve the lives of patients in the United States of America and Denmark. Its primary product, HMB-001, is a bispecific antibody currently undergoing Phase 1/2 clinical development for the preventative treatment of Glanzmann thrombasthenia. HMB-001 is also in Phase 2 clinical development for the preventative treatment of Factor VII deficiency. Another clinical-stage asset, HMB-002, is a monovalent antibody in Phase 1/2 clinical development. HMB-002 is designed for subcutaneous preventative treatment of Von Willebrand disease. In addition to its clinical programs, Hemab Therapeutics Holdings, Inc. is advancing several assets in preclinical and discovery stages. The company was established in 2020 and is headquartered in Cambridge, Massachusetts.

Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 14 items for COAG at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-10, rated 7/10. Across its 14 most recent items scored 7 or higher, the top rating is 9/10, with 8 rated 8 or above. Recent SEC coverage for COAG spans 8-K, 10-Q, SCHEDULE 13D, 4.

Recent high-impact activity:

  • Hemab Posts $27.3M Q3 Loss, Starts Pivotal SOLARA Phase 3 in Glanzmann Thrombasthenia
  • Sutacimig Cuts Prothrombin Time Over 50% After Single Dose in Two Patients
  • Hemab Doses First Patient in Phase 1 Trial of HMB-003 for Heavy Menstrual Bleeding
  • Hemab Posts Q2 Loss, Extends Cash Runway to 2029, but Flags Unremediated Material Weaknesses
  • Hemab Posts Q2 Loss of $24.2M, Gets FDA Nod for Phase 3 Trial

Short Interest & Short Volume

7.31 days to cover

FINRA reported short interest of 3,305,474 shares in COAG as of the October 30, 2026 settlement, a 4.6% increase from the prior period — about 7.3 days to cover at its recent average daily volume. On November 20, 2026, 86.3% of COAG volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)3,305,474 shares as of October 30, 2026
Change vs prior period▲ 4.6%
Days to cover7.31 at avg daily volume of 451,955
Daily short volume (FINRA facilities)86.3% of 141,102 shares on November 20, 2026
5-day average short volume84.6%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with C →
$39.29
52-week range · as of 2026-11-10 $23 – $55.42
Market cap
$1.84B
Volume
347K (0.8× avg)
3-mo avg 454K
Live data · 2026-11-22 12:40 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed COAG - Latest Insights

COAG
Nov 10, 2026, 7:08 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $42.81
Real-time Price: $39.29 info
Change: -$3.52 (-8%) info
Market Cap: $1.836B info
COAG
Nov 04, 2026, 9:05 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $43.10
Real-time Price: $39.29 info
Change: -$3.81 (-9%) info
Market Cap: $1.836B info
COAG
Sep 17, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $40.97
Real-time Price: $39.29 info
Change: -$1.68 (-4%) info
Market Cap: $1.836B info
COAG
Aug 11, 2026, 4:00 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $51.74
Real-time Price: $39.29 info
Change: -$12.45 (-24%) info
Market Cap: $1.836B info
COAG
Aug 11, 2026, 7:50 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $49.87
Real-time Price: $39.29 info
Change: -$10.58 (-21%) info
Market Cap: $1.836B info
COAG
Aug 11, 2026, 7:11 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $49.87
Real-time Price: $39.29 info
Change: -$10.58 (-21%) info
Market Cap: $1.836B info
COAG
May 21, 2026, 4:11 PM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $26.30
Real-time Price: $39.29 info
Change: +$12.99 (+49%) info
Market Cap: $1.836B info
COAG
May 21, 2026, 4:02 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $27.50
Real-time Price: $39.29 info
Change: +$11.79 (+43%) info
Market Cap: $1.836B info
COAG
May 21, 2026, 7:05 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $26.46
Real-time Price: $39.29 info
Change: +$12.83 (+48%) info
Market Cap: $1.836B info
COAG
May 11, 2026, 4:43 PM EDT
Filing Type: SCHEDULE 13D
Importance Score:
8
Price at Filing: $25.00
Real-time Price: $39.29 info
Change: +$14.29 (+57%) info
Market Cap: $1.836B info
COAG
May 06, 2026, 7:16 PM EDT
Filing Type: 4
Importance Score:
9
Price at Filing: $24.85
Real-time Price: $39.29 info
Change: +$14.44 (+58%) info
Market Cap: $1.836B info
COAG
May 04, 2026, 4:09 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $25.34
Real-time Price: $39.29 info
Change: +$13.95 (+55%) info
Market Cap: $1.836B info
COAG
May 01, 2026, 4:14 PM EDT
Filing Type: 424B4
Importance Score:
9
Price at Filing: $33.15
Real-time Price: $39.29 info
Change: +$6.14 (+19%) info
Market Cap: $1.836B info
COAG
Apr 30, 2026, 6:55 PM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: N/A
Real-time Price: $39.29 info
Change: N/A info
Market Cap: $1.836B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets